<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Dig Dis Sci</journal-id><journal-id journal-id-type="iso-abbrev">Dig. Dis. Sci.</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Digestive diseases and sciences</journal-title></journal-title-group><issn pub-type="ppub">0163-2116</issn><issn pub-type="epub">1573-2568</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5106301</article-id><article-id pub-id-type="pmcid-ver">PMC5106301.1</article-id><article-id pub-id-type="pmcaid">5106301</article-id><article-id pub-id-type="pmcaiid">5106301</article-id><article-id pub-id-type="manuscript-id">NIHMS823358</article-id><article-id pub-id-type="pmid">27743164</article-id><article-id pub-id-type="doi">10.1007/s10620-016-4340-x</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS823358</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA823358</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sofosbuvir containing regimens for chronic hepatitis C are successful in the safety-net population: A real world experience</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Beck</surname><given-names initials="KR">Kendall R</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="N">Nicole</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khalili</surname><given-names initials="M">Mandana</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medicine, University of California San Francisco, San Francisco, CA, USA</aff><aff id="A2"><label>2</label>Liver Center, University of California San Francisco, San Francisco, CA, USA</aff><author-notes><corresp id="cor1">Corresponding Author: Mandana Khalili, M.D., University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, NH 3-D, San Francisco, CA 94110, USA, <email>Mandana.Khalili@ucsf.edu</email>, Tel 415-206-4766, Fax 415-641-0745</corresp><fn fn-type="COI-statement" id="FN1"><p id="P23"><bold>Conflicts of interest:</bold> There are no conflicts of interest in connection with the submitted manuscript.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><volume>61</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">278919</issue-id><fpage>3602</fpage><lpage>3608</lpage><pub-history><event event-type="nihms-submitted"><date><day>18</day><month>10</month><year>2016</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 04:25:13.040"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms823358.pdf"/><abstract><sec id="S1"><title>Background</title><p id="P1">Vulnerable populations are disproportionately affected by hepatitis C virus infection (HCV), and experience high rates of health disparity. There is no data on real world experience with highly efficacious direct acting anti-HCV (DAA) treatment in this population.</p></sec><sec id="S2"><title>Aims</title><p id="P2">We aimed to evaluate the real world experience with sofosbuvir-based regimens among a vulnerable HCV-infected population.</p></sec><sec id="S3"><title>Methods</title><p id="P3">HCV treatment response was assessed among 204 patients who completed 12&#8211;24 weeks of sofosbuvir (SOF)-based regimens (in combination with pegylated interferon and ribavirin, simeprevir, ledipasvir, or daclatasvir) at the San Francisco safety-net healthcare system liver specialty clinic between January 2014 and December 2015. Virologic response during therapy was assessed at weeks 4, 8, end of therapy, and 12 weeks treatment discontinuation (SVR 12).</p></sec><sec id="S4"><title>Results</title><p id="P4">Patient characteristics were median age 58 years, 60% male, 42% Caucasian (21% black, 19% Hispanic), 72% had genotype 1 (23% genotype 2 or 3), and the median baseline log<sub>10</sub> HCV viral load was 6.1 IU/ml and alanine transaminase 63 U/L. Cirrhosis was present in 36% (of whom 40% were decompensated) and 18% were HCV treatment experienced. Overall, SVR 12 was achieved in 97% (99% genotype 1, 100% genotype 2, 84% genotype 3). Five of six (83%) of patients who relapsed had decompensated cirrhosis and 67% were also non-adherent to therapy. On treatment virologic response did not impact SVR.</p></sec><sec id="S5"><title>Conclusions</title><p id="P5">High rates of sustained virologic response can be achieved in safety-net HCV-infected patients. Access to DAA-based regimens is critical to addressing HCV-related health disparity in this at risk population.</p></sec></abstract><kwd-group><kwd>HCV</kwd><kwd>direct acting antiviral therapy</kwd><kwd>underserved population</kwd><kwd>cirrhosis</kwd><kwd>sustained virologic response</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>